SUGAR LAND--March 23, 2016--Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas)--As the North American Pharmaceutical-Biotech Industry, which includes coverage of pharmaceuticals, biologicals, medical devices and cosmetics, continues to return a healthy capital expenditures (capex) investment profile, Europe's volume of project activity cannot be ignored. Barely months into the launch of the expansion of project coverage into Europe, over $14.5 billion in active capital and maintenance (MRO) activity across the pond has been identified and reported upon. Within this article: Description of Pharma-Biotech Development in Europe. Additional companies: GlaxoSmithKline (NYSE:GSK)